NASDAQ
MGTX

MeiraGTx Holdings PLC

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

MeiraGTx Holdings PLC Stock Price

Vitals

Today's Low:
$5.66
Today's High:
$6.15
Open Price:
$6.15
52W Low:
$4.77
52W High:
$9.37
Prev. Close:
$6.14
Volume:
123263

Company Statistics

Market Cap.:
$379.24 million
Book Value:
2.075
Revenue TTM:
$6.40 million
Operating Margin TTM:
-1943.27%
Gross Profit TTM:
$15.92 million
Profit Margin:
0%
Return on Assets TTM:
-27.64%
Return on Equity TTM:
-93.82%

Company Profile

MeiraGTx Holdings PLC had its IPO on 2018-06-08 under the ticker symbol MGTX.

The company operates in the Healthcare sector and Biotechnology industry. MeiraGTx Holdings PLC has a staff strength of 406 employees.

Stock update

Shares of MeiraGTx Holdings PLC opened at $6.15 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $5.66 - $6.15, and closed at $6.

This is a -2.28% slip from the previous day's closing price.

A total volume of 123,263 shares were traded at the close of the day’s session.

In the last one week, shares of MeiraGTx Holdings PLC have slipped by -5.81%.

MeiraGTx Holdings PLC's Key Ratios

MeiraGTx Holdings PLC has a market cap of $379.24 million, indicating a price to book ratio of 2.2204 and a price to sales ratio of 6.4573.

In the last 12-months MeiraGTx Holdings PLC’s revenue was $6.40 million with a gross profit of $15.92 million and an EBITDA of $-113549000. The EBITDA ratio measures MeiraGTx Holdings PLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, MeiraGTx Holdings PLC’s operating margin was -1943.27% while its return on assets stood at -27.64% with a return of equity of -93.82%.

In Q2, MeiraGTx Holdings PLC’s quarterly earnings growth was a positive 0% while revenue growth was a negative 67.1%.

MeiraGTx Holdings PLC’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MeiraGTx Holdings PLC’s profitability.

MeiraGTx Holdings PLC stock is trading at a EV to sales ratio of 5.9084 and a EV to EBITDA ratio of -2.4534. Its price to sales ratio in the trailing 12-months stood at 6.4573.

MeiraGTx Holdings PLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$310.26 million
Total Liabilities
$71.80 million
Operating Cash Flow
$-4975000.00
Capital Expenditure
$4.98 million
Dividend Payout Ratio
0%

MeiraGTx Holdings PLC ended 2024 with $310.26 million in total assets and $0 in total liabilities. Its intangible assets were valued at $310.26 million while shareholder equity stood at $123.53 million.

MeiraGTx Holdings PLC ended 2024 with $189000.00 in deferred long-term liabilities, $71.80 million in other current liabilities, 2000.00 in common stock, $-530149000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $92.77 million and cash and short-term investments were $92.77 million. The company’s total short-term debt was $4,126,000 while long-term debt stood at $71.57 million.

MeiraGTx Holdings PLC’s total current assets stands at $143.14 million while long-term investments were $6.33 million and short-term investments were $0. Its net receivables were $40.72 million compared to accounts payable of $28.50 million and inventory worth $8.11 million.

In 2024, MeiraGTx Holdings PLC's operating cash flow was $-4975000.00 while its capital expenditure stood at $4.98 million.

Comparatively, MeiraGTx Holdings PLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$6
52-Week High
$9.37
52-Week Low
$4.77
Analyst Target Price
$24

MeiraGTx Holdings PLC stock is currently trading at $6 per share. It touched a 52-week high of $9.37 and a 52-week low of $9.37. Analysts tracking the stock have a 12-month average target price of $24.

Its 50-day moving average was $6.28 and 200-day moving average was $6.51 The short ratio stood at 11.33 indicating a short percent outstanding of 0%.

Around 487.2% of the company’s stock are held by insiders while 6102.5% are held by institutions.

Frequently Asked Questions About MeiraGTx Holdings PLC

The stock symbol (also called stock or share ticker) of MeiraGTx Holdings PLC is MGTX

The IPO of MeiraGTx Holdings PLC took place on 2018-06-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$23.01
-0.87
-3.64%
$125.5
-13.15
-9.48%
Mogo Inc (MOGO)
$1.6
0.01
+0.63%
$16.42
-0.17
-1.02%
Nuvalent Inc (NUVL)
$46.98
-1.12
-2.33%
$10.2
-0.2
-1.92%
$3.48
-0.68
-16.3%
$0.06
0
0%
$1743.15
-7.3
-0.42%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

Address

430 East 29th Street, New York, NY, United States, 10016